文献速递痛风与晶体性关节病

无症状高尿酸血症患者对无症状高尿酸血症的认知及对降尿酸治疗的看法

Perceptions About Asymptomatic Hyperuricemia and Views About Urate-Lowering Therapy in People With Asymptomatic Hyperuricemia.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-11-26

该多国研究纳入筛查血清尿酸≥0.48 mmol/L(8 mg/dL)且无痛风症状的无症状高尿酸血症患者,通过问卷了解其对高尿酸血症的认知、对相关健康问题的担忧及服用降尿酸药物的意愿。多数患者认为高尿酸血症对生活无或几乎没有影响,37%不知道病因,对肾病和心血管病的担忧高于对尿酸升高的担忧(P < 0.001),多数认为降尿酸药物不必要。

要点

  • 多数无症状高尿酸血症患者认为该病对生活无或几乎没有影响,37%不知道病因。
  • 对肾病和心血管病的担忧高于对血清尿酸升高的担忧(P < 0.001)。
  • 多数患者认为降尿酸药物不必要,用药必要性信念与服药意愿关联最强(partial R2 = 0.27,P < 0.001)。

核心结论

  • 多数参与者认为无症状高尿酸血症对生活影响极小,对该病理解不足,生物性病因普遍认识不足。
  • 尽管对高尿酸血症相关疾病(尤其是肾病和心血管病)存在不同程度的担忧,但多数认为无症状高尿酸血症不需降尿酸药物,这与多数现行管理指南一致。

研究设计与样本

  • 多国研究,参与者为无症状高尿酸血症患者,完成关于高尿酸血症认知、对相关健康问题担忧及服用降尿酸药物意愿的问卷。
  • 所有参与者筛查血清尿酸≥0.48 mmol/L(8 mg/dL)且当前或既往无痛风症状。

主要发现

  • 参与者认为高尿酸血症对生活无或几乎没有影响。
  • 饮食因素是最常报告的病因,37%不知道病因。
  • 对高尿酸血症及发生痛风风险的担忧程度范围较广;对发生肾病或心血管病风险的担忧也高度可变,但高于对血清尿酸升高的担忧(P < 0.001)。
  • 多数认为降尿酸药物不必要,对长期使用降尿酸药物存在中度担忧。
  • 用药必要性信念与参与者是否愿意服用降尿酸药物关联最强(partial R2 = 0.27,P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Asymptomatic hyperuricemia is a precursor of gout and is also associated with cardiovascular disease and chronic kidney disease. The aim of this study was to understand perceptions about asymptomatic hyperuricemia and views about urate-lowering therapy in people with asymptomatic hyperuricemia. METHODS: Participants in a multinational study of asymptomatic hyperuricemia completed questionnaires about their perceptions of hyperuricemia, concern about hyperuricemia-associated health conditions, and willingness to take urate-lowering medication. All had a screening serum urate of ≥0.48 mmol/L (8 mg/dL) and no current or previous symptoms of gout. RESULTS: Overall, participants perceived that hyperuricemia had no or very few consequences on their life. Dietary factors were the most reported cause, whereas 37% did not know the cause. Participants reported a wide range in concern about hyperuricemia and the risk of developing gout. Concern about the risk of developing kidney disease or cardiovascular disease was also highly variable but was higher than concern about elevated serum urate (P < 0.001). Most did not think a urate-lowering medication was necessary, and there was moderate concern about the long-term use of urate-lowering medication. Medication necessity beliefs were most strongly associated with whether participants were willing to take urate-lowering medication (partial R2 = 0.27, P < 0.001). CONCLUSION: Most participants perceived minimal consequences of asymptomatic hyperuricemia. Hyperuricemia was not well understood by participants, and biologic causes were generally underrecognized. Despite a range of concerns about hyperuricemia-associated conditions, particularly kidney disease and cardiovascular disease, a urate-lowering medication for asymptomatic hyperuricemia was not considered necessary, which aligns with most current management guidelines.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Dalbeth N, Stewart S, Gamble GD, et al. Perceptions About Asymptomatic Hyperuricemia and Views About Urate-Lowering Therapy in People With Asymptomatic Hyperuricemia. Arthritis Care Res (Hoboken). 2025. PMID: 40884020. doi:10.1002/acr.25639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。